Clinical trial

A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of…

NCT00000656 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00000656
Title A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
Official title A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Collaborators Bristol-Myers Squibb Industry Glaxo Wellcome
Status Completed
Phase Phase 1
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Zidovudine, Didanosine
Enrollment 116
Completion Nov 1, 1993
First posted Aug 31, 2001
Last update posted Nov 3, 2021
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies